MSD India Managing Director K.G. Ananthakrishnan On Disease Management And Taking A Holistic Approach: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Merck Sharp & Dohme India Managing Director K.G. Ananthakrishnan discusses MSD’s holistic approach to patient care in India, including disease management, physician education and responsible pricing.
You may also be interested in...
With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
MUMBAI - In an attempt to add more teeth to its rapidly growing anti-diabetes franchise in India, Merck & Co.'s affiliate MSD India and Sun Pharmaceutical Industries Ltd. jointly announced the formation of an "India-specific strategic partnership" under which Sun will have the right to market, promote and distribute MSD's star products Januvia (sitagliptin) and Janumet (sitagliptlin/metformin) under different brand names